Feng R Luo

ACEA Therapeutics Inc.

San Diego, CA

United States

SCHOLARLY PAPERS

1

DOWNLOADS

6

CITATIONS

1

Scholarly Papers (1)

1.

A Modified Phase 1 Clinical Trial of Abivertinib (Ac0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M-positive Non-Small Cell Lung Cancer

Number of pages: 29 Posted: 06 Dec 2018
Government of the People's Republic of China - 307th Hospital, Government of the People's Republic of China - 307th Hospital, Chinese Academy of Medical Sciences, Zhejiang University, Chinese Academy of Medical Sciences, Central South University, Peking University - Cancer Hospital and Institute, Jilin Province Cancer Hospital, Chinese Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, ACEA Pharmaceutical Research, ACEA Therapeutics Inc., ACEA Therapeutics Inc., ACEA Therapeutics Inc. and Guangdong Academy of Medical Sciences, Guangdong General Hospital, Guangdong Lung Cancer Institute, Department of Pulmonary Oncology
Downloads 6 (604,068)

Abstract:

Loading...

abivertinib; AC0010; EGFR; NSCLC; T790M; Phase 1